Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics (Nasdaq: UTHR) announced that Chief Financial Officer and Treasurer James Edgemond will present a company overview and update at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, from 12:45 to 1:15 p.m. EST.
The presentation will be available via live webcast and as an archived recording on the United Therapeutics investor relations website for 90 days.
United Therapeutics (Nasdaq: UTHR) reported full phase 3 TETON-1 results of nebulized Tyvaso in idiopathic pulmonary fibrosis, published in the New England Journal of Medicine and presented at ATS 2026.
The study met its primary FVC endpoint and a key secondary clinical worsening endpoint; combined TETON-1/2 analyses showed multiple statistically significant efficacy outcomes. Tyvaso for IPF remains investigational.
United Therapeutics (Nasdaq: UTHR) reported full phase 3 ADVANCE OUTCOMES results for investigational ralinepag in pulmonary arterial hypertension (PAH) at ATS 2026.
Ralinepag cut risk of clinical worsening by 55% vs placebo, improved NT-proBNP by 24.3%, increased 6MWD by 20.4 m, and showed no new safety signals. An FDA New Drug Application is planned by 2H 2026.
United Therapeutics (Nasdaq: UTHR) received FDA clearance under its IND to begin EXPRESS, a first-ever human clinical trial of its investigational UHeart xenoheart, derived from a pig with 10 gene edits. The trial starts with up to two participants and may later expand to support a future Biologics License Application (BLA).
United Therapeutics (Nasdaq: UTHR) and Varda Space Industries announced a research collaboration to develop microgravity-enabled formulations of small-molecule treatments for rare, life-threatening pulmonary diseases. Multiple missions to low Earth orbit will use Varda's orbital manufacturing and W-series reentry capsules to process medicines in microgravity.
The partners aim to exploit microgravity's effects on crystallization to seek drug formulations that may improve stability, bioavailability, delivery methods, and efficiency of drug delivery to target sites.
United Therapeutics (Nasdaq: UTHR) announced that Chief Financial Officer and Treasurer James Edgemond will present a company overview and update at the RBC Capital Markets Global Healthcare Conference in New York.
The presentation is scheduled for May 19, 2026, from 9:30 to 9:55 a.m. EST and will be available via live webcast and a 90-day archived replay on the United Therapeutics investor relations website.
United Therapeutics (Nasdaq: UTHR) will present 12 new data sets at the ATS 2026 International Conference, held May 15-20 in Orlando. Key sessions cover TETON-1 and TETON-2 phase 3 trials of inhaled treprostinil in idiopathic and progressive pulmonary fibrosis and the phase 3 ADVANCE OUTCOMES trial of ralinepag in pulmonary arterial hypertension.
Additional presentations include interim analyses from TETON-PPF, PHINDER, and ARTISAN, plus multiple real-world and patient-reported outcome studies in pulmonary hypertension and interstitial lung disease.
United Therapeutics (Nasdaq: UTHR) reported Q1 2026 results with total revenue of $781.5M, down 2% year-over-year, and net income of $274.9M, down 15% year-over-year. Tyvaso DPI sales grew to $330.3M, while Nebulized Tyvaso declined. Cost of sales rose on higher inventory reserves, and R&D totaled $138.2M. The board authorized a $2.0B repurchase program and entered $1.5B accelerated repurchase agreements in March 2026.
Company highlighted positive clinical results from ADVANCE OUTCOMES and TETON-1 and announced development plans for ralinepag DPI.
United Therapeutics (Nasdaq: UTHR) announced that Professor Raymond Dwek will retire from the Board of Directors when his term expires at the 2026 Annual Meeting of Shareholders on June 26, 2026. Prof. Dwek joined the board in 2002 and will continue serving on the company’s Scientific Advisory Board. The Board approved a reduction in size from 13 to 12 members, effective at the 2026 Annual Meeting.
The release highlights Prof. Dwek’s scientific contributions in glycobiology and quotes leadership thanking him for his long service and impact on the company’s therapeutic programs.
United Therapeutics (Nasdaq: UTHR) will report Q1 2026 financial results on Wednesday, May 6, 2026 at approximately 6:30 a.m. Eastern Time. A public webcast will follow on May 6, 2026 at 9:00 a.m. Eastern Time and will be rebroadcast for one year.
Investors can access the live webcast and rebroadcast at the company investor website events and presentations page.